Home » Newsletters » BioWorld Science

BioWorld Science

June 5, 2003

View Archived Issues

Dual adenosine A1/A2A antagonists and their use reported by Fujisawa

Novel VEGFR kinase inhibitors identified by Novartis researchers

Immunogenic peptides with utility in HIV infection therapy

Pharmacia scientists claim new alpha7 nAChR agonists in recent patent

New IKK inhibitors in early development at Roche

Amine salts of alphavbeta3 integrin antagonist covered by Merck patent

Wyeth presents new estrogenic agents with utility in osteoporosis, cancer, IBD, etc.

Fujisawa licenses carperitide in North America and Europe

Revimid demonstrates potential in myelodysplastic syndromes

ICN to make tender offer for outstanding shares of Ribapharm

Anika seeks FDA approval for Orthovisc

Nicotine increases muscle girth, decreases body weight and reduces appetite in mice

RxKinetix acquires exclusive rights to RK-0202

Grant supports development of virus cell-based assay for anti-HIV drug discovery

PDL initiates trial of anti-alpha5beta1 integrin antibody in solid tumors

Nuvion development targeted for ulcerative colitis

Oralin set to enter phase IIb shortly

Enrollment completed in Atrisone phase III studies

Baxter launches Aralast

Tricyclic quinoxalines as potential new agents for restenosis and cancer

Advexin able to stop progression of advanced esophageal cancer

AP-2238, the prototype of a novel class of AD therapeutics

Phase I clinical trial results for Bay-43-9006 summarized at ASCO

Phase I clinical evaluation initiated for HIV-based lentiviral vector from VIRxSYS

EMD-72000 shows good tolerability and evidence of antitumor activity in phase I trials

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...